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ABSTRACT
Background. In synovial sarcomas alterations in the
cyclin D1-CDK4/6-Rb axis have been described. Also,
b-catenin, a cyclin D1 regulator, is often overexpressed.
Additionally, studies have shown that the t(X;18) translo-
cation influences tumor behavior partly through cyclin D1
activation. We investigated how alterations in the cyclin
D1-CDK4/6-Rb axis impact prognosis and studied effects
of targeting this axis with the CDK4/6 inhibitor
palbociclib.
Methods. Synovial sarcoma samples (n = 43) were
immunohistochemically stained for b-catenin, cyclin D1,
p16, p21, p27, Rb, and phospho-Rb. Fluorescent in situ
hybridization (FISH) was performed to detect CCND1
amplification or translocation. In 4 synovial sarcoma cell
lines sensitivity to palbociclib was investigated using cell
viability assays, and effects on the sensitive cell lines were
evaluated on protein level and by cell cycle arrest.
Results. Expression of nuclear phospho-Rb and nuclear
b-catenin in the patient samples was associated with poor
survival. FISH showed a sporadic translocation of CCND1
in a subset of tumors. An 8-fold CCND1 amplification was
found in 1 cell line, but not in the patient samples inves-
tigated. Palbociclib effectively inhibited Rb-phosphory
lation in 3 cell lines, resulting in an induction of a G1 arrest
and proliferation block.
Conclusions. In this series nuclear phospho-Rb and
nuclear b-catenin expression were negative prognostic
factors. In vitro data suggest that palbociclib may be a
potential treatment for a subset of synovial sarcoma
patients. Whether this effect can be enhanced by combi-
nation treatment deserves further preclinical investigations.
Synovial sarcoma (SyS) is a subtype of soft tissue
sarcomas (STS), characterized by a chromosomal transloca-
tion t(X;18). Localized disease is treated with surgery,
occasionally with additional radiotherapy or chemotherapy.
Palliative chemotherapy can be given once patients have
advanced disease, with poor survival rates. Although the field
of targeted treatment for carcinomas is developing rapidly,
trials with targeted therapies for rare cancers such as sarcoma
are scarce, and pazopanib is currently the only registered
targeted treatment for non-gastrointestinal stromal tumor
(GIST) STS, including SyS.1 To improve prognosis for this
group of patients, knowledge on actionable targets in this
sarcoma subtype is desperately needed. Among others, cyclin
D1 has been suggested as a potential therapeutic target.
Cyclin D1 is a cell cycle regulator essential for progression
from G1 to S phase. Deregulated expression via mutations,
gene rearrangements, or amplification of CCND1 has been
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reported in various cancer types.2–4 Also alterations of other
proteins involved in the cyclin D1-CDK4/6-Rb axis (e.g.,
p16, retinoblastoma (Rb) protein, and p21) may lead to
uncontrolled progression through the cell cycle.5,6 Even
though the exact working mechanism of the SyS translocation
is still unknown, it has been shown that the SS18-SSX fusion
gene is associated with cyclin D1 expression in SyS cells.
Downregulation of the fusion gene expression by siRNA
drastically decreased cyclin D1 levels, resulting in reduced
cell proliferation.7–9 To further investigate the axis through
which cyclin D1 is affected, several mechanisms have been
postulated.
Cai et al. demonstrated that siRNA-mediated downreg-
ulation of the SS18-SSX2 gene product in SyS cell lines
resulted in a decreased expression of (phospho)-ERK1/2
and cyclin D1, suggesting a direct link between this
translocation and ERK1/2 and cyclinD1 activation.10 This
was supported by a study showing that inhibition of the
MEK/ERK-pathway with sorafenib led to downregulation
of the expression of cyclin D1 and Rb protein with con-
secutive cell cycle arrest.11 It has also been suggested that
the translocation associates with deregulated cyclin D1
activity via the Wnt/b-catenin-pathway. Indeed, this ‘‘cel-
lular dedifferentiation’’ pathway is constitutively active in
a SYT-SSX2 transgenic mouse model, with corresponding
cyclin D1 expression, and inhibition of Wnt signaling
through functional knock-out of the b-catenin gene reduced
tumor formation.12,13 In line with this, blocking b-catenin
with small molecule inhibitors in SyS cell lines resulted in
cyclin D1 downregulation.14 Moreover, cyclin D1 activity
could also be regulated by the PI3K/Akt-pathway. In vitro,
PI3K inhibition resulted in decreased cell proliferation,
which was linked to reduced cyclin D1 and increased levels
of p27.15 Others have shown that cyclin D1-positive and
nuclear b-catenin negative SyS were positive for phospho-
Akt.16 It has also been suggested that the SSX2 gene
product stimulates miR-17 expression, which subsequently
inhibits p21.17 Additionally, heterozygous loss of p16 has
been reported in SyS tumors, and recently we reported the
occurrence of a CCND1 mutation with additional nuclear
overexpression of cyclin D1 in a patient sample.18–20
All these studies suggest that the cyclin D1-CDK4/6-Rb
axis integrates inputs from the Wnt/b-catenin, PI3K/AKT,
and ERK-pathways in SyS making the cyclin D1-CDK4/6-
Rb axis an interesting target for treatment of SyS patients.
However, so far no published data is available on the
specific exploration of inhibiting this target in SyS. One
such potential active drug could be palbociclib. Palbociclib
(PD-0332991) is a highly selective drug, inhibiting the
CDK4/6-cyclin D1 kinase activity while showing little or
no activity to other enzymes. It was proven to reduce Rb
phosphorylation at the 2 sites that are specifically phos-
phorylated by CDK4 and CDK6. Significant antitumor
activity was detected only at doses where there was a
sustained and significant reduction of these sites on Rb.21
Palbociclib has recently been FDA approved for the
treatment of postmenopausal women with estrogen recep-
tor (ER)-positive, human epidermal growth factor receptor
2 (HER2)-negative advanced breast cancer as initial ther-
apy in metastatic disease in combination with letrozole. In
sarcoma, the only phase 2 studies have been performed in
liposarcoma.22 In SyS, no study on palbociclib has been
done yet. Therefore, we here evaluated the cyclin
D1-CDK4/6-Rb axis and tested palbociclib as a possible
treatment for SyS patients.
MATERIALS AND METHODS
Patient Characteristics
Tumor samples from 43 patients, diagnosed with SyS
between 1988 and 2015, were retrieved from the files of the
department of Pathology of the Radboud University Med-
ical Centre (Radboud UMC). Patient follow-up data was
retrieved from the clinical records. The study was per-
formed in accordance with the Code of Conduct of the
Federation of Medical Scientific Societies in the
Netherlands.
Immunohistochemistry
Immunohistochemistry for cyclin D1, p16, p21, p27, b-
catenin, Rb, and phospho-Rb was performed on 4-lm thick
formalin-fixed paraffin-embedded (FFPE) tissue microarray
(TMA) sections using standard procedures. The specifica-
tions for each antibody are listed in Supplemental Table 1.
After incubation with primary antibody and washing, anti-
bodies were visualized using PowerVision poly-HRP-anti-
Ms/Rb/Rt (ImmunoLogic), visualized using bright 3,30-di-
aminobenzidine (DAB, ImmunoLogic) and counterstained
with hematoxylin. Immunostaining was scored by 3 indi-
vidual researchers, and consensus was reached (scoring
systems are explained below in Fig. 1 and Supplemental
Fig. 1). Only results from primary tumors were included in
the analysis, in order to obtain a representative view on
survival. A Kaplan–Meier analysis was performed with a
log-rank test to calculate survival differences, which were
considered to be significant at p\ 0.05.
FISH
For the detection of gene rearrangements, fluorescent
in situ hybridization (FISH) was performed on 2-lm thick
FFPE TMA sections that were pretreated in sodium citrate
buffer (pH6) by heating in a microwave oven for 10 min,
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followed by a digestion step with pepsin (200 U/ml) for
15 min at 37 C. The CCND1 DNA split probe (Y5414,
DAKO) was applied to the sections and heat denatured for
5 min at 82 C and hybridized at 45 C overnight. Sec-
tions were mounted in Vectashield mounting medium with
DAPI (Vector Laboratories). Fifty cells were counted,
and[10 % fusion breakage was considered a transloca-
tion. Amplifications were considered when[6 CCND1
signals were detected in[10 % of the cells.
Cell Culture
The 2 patient-derived SyS cell lines harboring the SSX1
translocation (Yamato-SS and Aska-SS) were generously
provided by K. Itoh. The 2 patient-derived SyS cell lines
harboring the SSX2 translocation (SYO-1 and CME-1)
were generously provided by A. Kawai and C. Lanzi,
respectively. Yamato-SS and Aska-SS were cultured in
DMEM 4.5 g/l glucose (Lonza), 1 mM sodium pyruvate
(PAA) medium, SYO-1 in DMEM 4.5 g/l glucose, and
CME-1 in RPMI-1640 medium (Lonza). Media were sup-
plemented with 10 % fetal bovine serum (FBS, Gibco) and
1 % penicillin/streptomycin (Lonza). All cells were main-
tained at 37 C in a humidified atmosphere of 5 % CO2/
95 % air.
MTT Assay
Cell viability (defined as metabolic cell activity) was
assessed by MTT assay. Cells were seeded in triplicate in
96-well plates overnight for attachment and then incubated
for 2 times the doubling time of the cell line, with
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FIG. 1 Proteins involved in the cyclin D1-CDK4/6-Rb axis. A Both
nuclear (N) staining of b-catenin and nuclear (N) staining of phospho-
Rb was scored as negative or positive. The cutoff was set at staining
in at least 20 % of the cells. All images are taken at 9200
magnification, insets are at 9400 magnification. B Levels of the
proteins involved in the cyclin D1-CDK4/6-Rb axis on western blot.
Different expression levels can be seen between the 4 synovial
sarcoma cell lines. C Kaplan–Meier survival curves for b-catenin and
phospho-Rb expression levels, which resulted in an overall survival
difference
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palbociclib (PD-0332991, Pfizer) (0–10,000 nM). Next,
MTT (Sigma-Aldrich) was added to each well and cells
were incubated for 3.5 h. Afterward, the formazan crystals
were dissolved in MTT solvent (isopropanol with 0.1 %
Nonidet P-40 and 4 mM fuming hydrochloric acid) and
absorbance was measured at 560 nm using an ELISA
reader. IC50 values were calculated using GraphPad Prism
Version 5.03 software.
Cell Cycle Assay
SyS cells were dissociated with trypsin and fixated in
70 % ethanol after treatment with different concentrations
of palbociclib at different time points. Propidium iodide
solution (Sigma-Aldrich, 50 lg/ml in PBS) was added to
the fixated cells to achieve DNA staining, and cells were
treated with RNAse A (Qiagen, 100 lg/ml). All samples
were measured using flow cytometry (CyAn ADP Ana-
lyzer, Beckman Coulter) and analyzed by FlowJo software
(version 10). Hereby viable single cells were selected by
gating.
Western Blot
After treatment of cells with different concentrations of
palbociclib, cells were trypsin-harvested and proteins
extracted with RIPA buffer (Cell Signaling Technology),
supplemented with 1 mM PMSF were loaded (40 lg of
cell extract, determined using the BCA protein assay kit,
Thermo Fisher Scientific) and separated by SDS-PAGE
under reducing conditions and subsequently transferred to
nitrocellulose membranes (Protan). Primary antibodies
were incubated overnight at 4 C (Supplemental Table 1).
Next, the blots were incubated with a goat-anti-rab-
bit/mouse IgG Alexa Fluor 680 conjugated secondary
antibody (Thermo Fisher Scientific). a-Tubulin was used as
loading control. The fluorescent signals were analyzed with
the Odyssey CLx Infrared Imaging System (LI-COR Bio-
sciences) and Image Studio Analysis Software Version 4.0.
TABLE 1 Patient characteristics
Parameter Frequency (%) n = 43
Age
Children\ 18 years 10 (23.3 %)
Adults C 18 years 33 (76.7 %)
Sex
Male 28 (65.1 %)
Female 15 (34.9 %)
Tumor localization
Extremities 27 (62.8 %)
Head/neck 6 (14.0 %)
Other 5 (11.6 %)
Unknown 5 (11.5 %)
Histology
Monophasic 17 (39.5 %)
Biphasic 13 (30.2 %)
Unknown 13 (30.2 %)
Neoadjuvant treatment
None 34 (79.1 %)
Chemotherapy 3 (7.0 %)
Radiotherapy 0
Unknown 6 (14.0 %)
Expression of nuclear cyclin D1
Negative 12 (27.9 %)
Positive 29 (67.4 %)
Missing 2 (4.7 %)
Expression of nuclear Rb
Negative 33 (76.7 %)
Positive 9 (20.9 %)
Missing 1 (2.3 %)
Expression of nuclear phospho-Rb
Negative 31 (72.1 %)
Positive 11 (25.6 %)
Missing 1 (2.3 %)
Expression of cytoplasmic p16
Low 27 (62.8 %)
High 12 (27.9 %)
Missing 4 (9.3 %)
Expression of nuclear p21
Negative 34 (79.1 %)
Positive 6 (14.0 %)
Missing 3 (7.0 %)
Expression of cytoplasmic p27
Low 25 (58.1 %)
High 16 (37.2 %)
Missing 2 (4.7 %)
Expression of b-catenin
Nuclear
Negative 11 (25.6 %)
Positive 30 (69.8 %)
TABLE 1 continued
Parameter Frequency (%) n = 43
Missing 2 (4.7 %)
Cytoplasmic
Negative 7 (16.3 %)
Positive 34 (79.1 %)
Missing 2 (4.7 %)
Membranous
Negative 30 (69.8 %)
Positive 11 (25.6 %)
Missing 2 (4.7 %)
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All experiments, including MTT assays, cell cycle
assays and western blots, were performed in duplicate.
Mutation analysis
For all 4 SyS cell lines the mutation hot spots of TP53
(exon 4–9) were analyzed by PCR amplification using the
AmpliTaq Gold 360 Master Mix (Life Technologies) with
1 ll DNA and the following program: 95 C (10 min);
95 C (30 s), 58 C (30 s), 72 C (1 min), 38 cycles; and
72 C for 7 min. Samples were submitted to Sanger DNA
sequencing using the BigDye Terminator reaction mix, and
samples were analyzed on the 3730 Sequence Analyzer
(Applied Biosystems). The known CTNNB1 G34L muta-
tion was verified in the SYO-1 cell line. All exons (1–5) of
CCND1 were sequenced as described previously.20
RESULTS
Clinical Data
Only 3 of 43 patients (7 %) were treated with neoad-
juvant chemotherapy (including 1 patient\18 years), none
had neoadjuvant radiotherapy, and of 14 % treatment status
was unknown. Survival data was available for 31 patients
(72 %).
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FIG. 3 Western blot and cell cycle
analysis. A Protein evaluation by
western blot shows a decrease in
phospho-Rb at increasing
concentrations of palbociclib at
different time points in the Yamato-SS,
Aska-SS and SYO-1 cell lines. As
expected, no effect can be seen on
cyclin D1 expression. B This column
shows the cell cycle analysis. The bars
indicate the G0/G1 phase, and show an
increase in G0/G1 arrest in Yamato-SS,
Aska-SS and SYO-1 cell lines
FIG. 2 Genetic alterations. CCND1 breakage in patient tumor sample (left), as indicated by the arrows and CCND1 amplification in the Yamato-
SS cell line (right) by FISH analysis
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Protein Evaluation by immunohistochemistry and
western blot
A total of 43 primary tumors were immunohistochemi-
cally stained for cyclin D1, p21, p27, p16, b-catenin,
phospho-Rb, and Rb (Fig. 1a, Supplementary Fig. 1). Of the
patient samples, 72.1 % had detectable expression of nuclear
cyclin D1 (Table 1). Expression of both nuclear phospho-Rb
and nuclear b-catenin was an indicator of poor prognosis
(Fig. 1c, p\ 0.05). We observed a significant correlation
between Rb and phospho-Rb (p = 0.005). No correlation
was found between expression ofb-catenin and phospho-Rb.
The 4 SyS cell lines were evaluated for expression of the
same proteins by western blot. Expression levels differed
between the cell lines (Fig. 1b). The Yamato-SS had the
highest expression of cyclin D1, whereas the CME-1 cell
line expressed a high level of p16, with a corresponding
lower level of cyclin D1.
Genetic Alterations
FISH analysis showed sporadic breakage, in 10–20 % of
the cells, of CCND1 in 15 % of the patient samples.
Additionally, an 8-fold amplification of CCND1 was found
in the Yamato-SS cell line (Fig. 2). The known CTNNB1
G34L mutation was confirmed in the SYO-1 cell line.14
The Yamato-SS cell line harbored a homozygous TP53
mutation in exon 8 (c.817C[T/p.R273C, rs121913343).
This deactivating TP53 mutation could explain the lack of
downstream target p21 found by western blot. None of the
cell lines harbored a mutation in CCND1.
Palbociclib sensitivity in vitro
MTT assays revealed a dose-dependent growth inhibi-
tion by palbociclib in all cell lines, in which 3 cell lines
(Yamato-SS, Aska-SS, and SYO-1) had an IC50 value of
0.83 lM ± 0.16, 0.98 lM ± 0.17, and 0.12 lM ± 0.01,
respectively. Since a concentration below 1.2 lM is con-
sidered feasible as plasma concentration in patients, IC50
values below this concentration are considered sensitive.23
The CME-1 cell line had an IC50 value of 8.0 lM ± 1.32
and is therefore regarded resistant to palbociclib. Palboci-
clib resulted in a concentration-dependent reduction of
phospho-Rb levels, already observed after 4 h of incuba-
tion. Inhibition of Rb phosphorylation was best seen at
24 h (Fig. 3a). Evaluation of the G1 arrest was done by
analyzing DNA content of the cells (propidium iodide
staining) (Fig. 3a). A G0/G1 arrest was induced in the 3
sensitive cell lines at 24 h. In the resistant CME-1 cell line
no effect of palbociclib on the cell cycle was observed
(data not shown).
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FIG. 4 Cyclin D1-CDK4/6-Rb axis. Highlighted are the proteins that have been investigated by immunohistochemistry and western blot
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DISCUSSION
Palbociclib is a well-tolerated drug with significant
progression-free survival (PFS) benefit in patients, in
combination with letrozole, for the treatment of post-
menopausal women with ER-positive, HER2-negative
advanced breast cancer as initial therapy for their meta-
static disease.24 Patients with STS have been tested for
palbociclib as well. A phase II study in well-differentiated
and dedifferentiated liposarcoma patients showed a partial
response in 1 of 29 evaluable patients, with a median PFS
of 18 weeks.22 Even though the cyclin D1-CDK4/6-Rb
axis has been thought to play a role in SyS, so far no
studies have reported on the effects of inhibiting this axis in
SyS. Here, we used patient tumor samples and 4 SyS cell
lines to evaluate genetic alterations of CCND1 and the
expression patterns of the proteins playing a possible role
in deregulation of this axis (Fig. 4). We showed CCND1
amplification in a SyS cell line and CCND1 rearrangement
in a small percentage of cells in a subset of patient samples,
although possible fusion partners and the significance of
these rearrangements in a small subset of tumor cells
remain elusive. Even though cyclin D1 is regularly repor-
ted to be a downstream target of several possibly activated
pathways in SyS, potentially induced by its fusion gene, the
exact working mechanism of the translocation in respect to
cyclin D1 remains unknown. We show a significant rela-
tion between nuclear b-catenin expression and overall
survival of SyS patients, which is in line with previous
studies.16,25 We provide information on the different
localizations of b-catenin expression (Table 1); however,
as only the nuclear expression has effect on cyclin D1, we
used this localization for prognostic evaluation. In addition,
we show that nuclear expression of phospho-Rb correlates
with overall survival. This might be a new potential
prognostic indicator, and further validation is needed in a
larger cohort.
Based on the presumed involvement of deregulated
cyclin D1 activity in SyS, we used palbociclib, a potent
inhibitor of this axis, in 4 SyS cell lines. Interestingly,
previous studies showed that palbociclib was considerably
less active in a number of non-synovial soft tissue sarcoma
cell lines (IC50 values of 8.95–26.63 lM), suggesting that
an aberrant cyclin D1-CDK4/6-Rb axis is a specific feature
for the SyS subtype of soft tissue sarcomas.26 One SyS cell
line had a noticeably higher IC50 (CME-1), probably
explained by the immortalization with SV40 large T anti-
gen. This binds to p53 and affects p53 transcriptional
activity. SV40 large T antigen also affects Rb activity,
which leads to a bypassing of the G1/S checkpoint with a
resulting constitutive activation of the cell cycle.27,28
As palbociclib does not result in a 100 % G1 arrest,
combination therapy will be necessary to induce the effect,
which may thus potentially translate into higher activity in
the clinic. Numerous potential combination therapies can
be investigated, including various chemotherapeutics,
small molecule inhibitors, and targeted antibodies, etc.
Very recently, a new insight in the translocation and the
Wnt pathway was established with a study reporting that
the translocation induces a partial Wnt expression signature
in the absence of Wnt ligands, using b-catenin as a tran-
scriptional de-repressor.29 With these functional studies,
insight into the pathophysiology improves, which will
hopefully result in rationale-based combination treatments.
In conclusion, this study shows an extensive overview
on the activity of the cyclin D1-CDK4/6-Rb axis in SyS, in
which genetic deregulation of CCND1 is rare. Further
research is necessary to examine the potential signaling
mechanisms between this axis and b-catenin, as this was
not subject of our research. Nuclear phospho-Rb and b-
catenin expression is correlated negatively with overall
survival in SyS patients, which has a potential prognostic
role, but should be validated in a separate dataset. Palbo-
ciclib induces a cell cycle arrest with corresponding
phospho-Rb decrease in SyS cell lines, making palbociclib
a potential treatment option for SyS patients. Whether this
effect can be enhanced by combination treatments deserves
further preclinical investigations.
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